

Invitation to presentation of BICO's Q3 results 2022

BICO's interim report for the third quarter that ended on September 30, 2022, will be published in English and Swedish on Wednesday November 9, 2022, at 07:00 am CEST.

Following the release of the report, a combined presentation webcast and telephone conference with the opportunity to ask questions will be held in English at 09:00 am CEST on the same day, with President & CEO Erik Gatenholm and Interim CFO Mikael Engblom presenting the report.

The presentation will be accessible via the following link:

Webcast, at 09:00 am CEST:

<https://ir.financialhearings.com/bico-q3-2022>

To participate via telephone, please call any of the following numbers:

SE: +46 8 505 16 386

UK: +44 203 198 48 84

US: +1 412 317 6300

Pin: 6705948#

The presentation will also be available on the company's website:

<https://bico.com/investors/financials/financial-reports-and-presentations/>

For further information, please contact:

Åsa Hillsten, SVP & Head of Investor Relations, BICO Group AB

Phone: +46 70-081 81 17

Email: ash@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on October 26, 2022, at 07:00 (CEST).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the world's leading bioconvergence company, with three business areas: Biosciences, Bioautomation, and Bioprinting. BICO reduces the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry.

Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development in 3D, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people's health and lives. Our products are trusted by more than 3,500 laboratories, including the top 20 pharmaceutical companies. We have more than 32,000 instruments in the field in over 65 countries and have been cited in over 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

PRESS RELEASE
26 October 2022 07:00:00 CEST



Attachments

[Invitation to presentation of BICO's Q3 results 2022](#)